# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 08-06-2024 | 06-30-2024 | 10-Q | |
2 | 05-06-2024 | 03-31-2024 | 10-Q | |
3 | 03-13-2024 | 12-31-2023 | 10-K |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $8 price target.
RBC Capital analyst Gregory Renza reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $8 price target.
Cantor Fitzgerald analyst Eric Schmidt initiates coverage on ADC Therapeutics (NYSE:ADCT) with a Overweight rating.
HC Wainwright & Co. analyst Robert Burns maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target f...